|Bid||80.25 x 400|
|Ask||87.33 x 100|
|Day's Range||79.61 - 80.70|
|52 Week Range||55.80 - 81.76|
|PE Ratio (TTM)||13.17|
|Earnings Date||Feb 27, 2018|
|Forward Dividend & Yield||0.00 (0.00%)|
|1y Target Est||78.59|
Jan.09 -- Express Scripts CEO Tim Wentworth discusses mergers and acquisitions in the healthcare industry. He speaks with Bloomberg's Erik Schatzker at the J.P. Morgan Healthcare Conference in San Francisco.
Jan.09 -- Express Scripts CEO Tim Wentworth discusses the value of pharmacy benefit managers. He speaks with Bloomberg's Erik Schatzker at the J.P. Morgan Healthcare Conference in San Francisco.
- Inside Rx Generated $35 Million in Savings Since May 2017 - 30 new brand medications for weight loss, dermatology, gastrointestinal conditions and allergies now available FRANKLIN LAKES, N.J. , Jan. ...
Louis, Jan. 15, 2018-- Express Scripts Holding Company announced today its intention to release its 2017 fourth quarter and full year financial results on Tuesday, February 27, 2018, after the market closes ...
WASHINGTON, Jan. 11, 2018 /PRNewswire/ -- During a briefing on meaningful solutions for safer opioid prescribing with Congressional Representatives Ann McLane Kuster (D-NH) and Tom MacArthur (R-NJ), Express Scripts (ESRX) today announced that an initial 90-day review of its Advanced Opioid ManagementSM program shows that the comprehensive solution is protecting people using an opioid medication, particularly those taking an opioid for the first time. In the first 90 days since the program began on September 1, 2017, the company observed a nearly 60 percent reduction in the average days supply for patients receiving an opioid prescription for the first time, from 18.6 days supply per prescription claim before the launch of the program, to 7.5 days supply per claim after the start of the program.
ST. LOUIS , Jan. 10, 2018 /PRNewswire/ -- Accredo ® specialty pharmacy, a subsidiary of Express Scripts (NASDAQ: ESRX), has earned URAC's specialty pharmacy accreditation at its primary dispensing locations: ...
FRANKLIN LAKES, N.J. , Jan. 10, 2018 /PRNewswire/ -- Inside Rx, which administers a prescription savings program for the uninsured and underinsured, is helping more people access savings to prescription ...
How far off is Express Scripts Holding Company (NASDAQ:ESRX) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stockRead More...
Express Scripts shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 76 to 81.
Small biotech firm Spark Therapeutics (ONCE) recently announced a new gene therapy that is designed to treat a rare, inherited retinal disease that can cause blindness. Approved by the FDA, Luxturna costs $425,000 per eye, or $850,000 for both
A new drug, Luxturna, literally allows blind people to see. It does it by using a virus to insert new genes into patients’ eyes. This morning, Luxturna’s maker, Spark Therapeutics, is announcing the cost of this medical miracle: $425,000 per eye, or $850,000 a year.
The price is for Spark Therapeutics' Luxturna, approved by the FDA in December to treat a rare, inherited retinal disease that can lead to blindness.
ST. LOUIS , Jan. 2, 2018 /PRNewswire/ -- Express Scripts Holding Company (Nasdaq: ESRX) (" Express Scripts ") announced today that it will present at the J.P. Morgan Healthcare Conference on ...
In September 2017, Express Scripts Holding Company (NASDAQ:ESRX) released its most recent earnings announcement, which revealed that the company gained from a strong tailwind, eventuating to a double-digit earnings growthRead More...
The tax plan is designed to kick-start economic growth in part by offering new incentives for capital investment, which would allow businesses to lower their tax bills by writing off the cost of things like new machinery more quickly. The tax reform includes cuts to corporate tax rates and a cap on business deductions for debt interest payments among others. The reinsurer said on Friday it expects to write down a portion of its deferred tax asset and currently estimates that this anticipated write-down will reduce its net income by about $40 million in the period in which the tax bill is enacted.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Express Scripts Holding Co. Here are 5 ETFs with the largest exposure to ESRX-US. Comparing the performance and risk of Express Scripts Holding Co. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more (Read more...)
A Relative Strength Rating upgrade for Express Scripts shows improving technical performance. Will it continue?